Answers are grounded in this paper and cite their sources.
Conceptual framework reveals potential microglial reprogramming strategies in Alzheimer's disease, suggesting dual-stage immune reset and metabolic activation could slow disease progression.
Alzheimer’s disease (AD) is increasingly recognized as a disorder involving not only amyloid-β (Aβ) and tau pathology but also profound neuroimmune dysregulation. Microglia, the resident immune cells of the central nervous system, progressively transition from protective homeostatic states toward chronically activated phenotypes characterized by excessive inflammation, impaired plaque containment, and neuronal injury. Two emerging therapeutic strategies target complementary aspects of this dysfunction: pharmacological inhibition of the cGAS-STING innate immune pathway and OLE-mediated microglial reprogramming through the PM20D1 pathway. STING inhibition reduces pathological type I interferon signaling and chronic neuroinflammation, whereas OLE (N-oleoyl-leucine) enhances cellular metabolism and promotes protective microglial functions. This article proposes a dual-layer therapeutic framework in which STING inhibition acts as an initial inflammatory reset, creating a permissive environment for subsequent OLE-driven functional reprogramming. Although the combined approach remains untested experimentally, its complementary mechanisms suggest a promising strategy for restoring microglial homeostasis and slowing Alzheimer’s disease progression.
No takes yet. Share an insight, caveat, or question.
Mireia Marina Santamaría (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: